SOX2-expressing cells are resistant to TMZ, but targeting SOX2 with inhibitors such as rapamycin has been shown to sensitize GBM cells to treatment,159 suggesting a potential strategy to increase therapeutic efficacy. This evidence concerns the gene SOX2 and glioblastoma.